Goldman Sachs is turning bullish towards GE Healthcare as the outlook for the Chinese market improves. Analyst David Roman upgraded his shares in medical technology stocks to buy from Neutral, increasing his price target from $15 to $100. The refreshed target for Rome's stocks means 17.2% advance, surpassing Monday's closure level. Roman said the company's previous paper on the stock revolved around a 4% to 5% growth in the company's basic business, which was offset by headwinds in sales in China. Now he said domestic sales are stable and could return to 2023 levels by 2026. Roman also increased its annual earnings per share forecast between 2025 and 2028. Although President Donald Trump's tariff policies remain a bulge in his paper, the company should not be uniquely affected by taxation. “We believe… China's faster transformation and leverage (of profits and declines) can do more than offset known tariff risks,” Roman said. “Like Global Medtech overall, it is difficult to quantify the risk of potential tariffs in the future, but GE Healthcare does not believe that it is disproportionately exposed to Mexico, Canada or the EU against other companies.” Roman's upgrade has made him a majority among analysts. According to LSEG, the majority of surveyed members also have a buy rating. Stocks rose 1.8% locally on Tuesday. The stock price added over 9% in 2025, backing the broader market downward trend.
